Capital Management Associates Inc. acquired 5,900 shares of Quest Diagnostics for about $1.024 million. Quest exceeded Q4 estimates, raised its FY2026 guidance, increased dividends, and announced a $1 billion buyback. Analysts have a "Hold" rating, with target prices up to $225.

NodeGuardian

2026-04-14 23:21:50

Abstract generation in progress

Capital Management Associates Inc. has acquired a new stake of 5,900 shares in Quest Diagnostics (NYSE:DGX) valued at approximately $1.024 million, making it part of an investor base that is largely institutionally owned. Quest Diagnostics recently surpassed Q4 estimates, provided strong FY2026 guidance, increased its dividend, and authorized a $1.0 billion share buyback. Analysts currently hold a “Hold” consensus rating with an average target price of $211.46, although some have raised their targets to $220–$225.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes

Reward
1
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
112.58K Popularity
#
GateMarchTransparencyReport
38.11K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
773.08K Popularity
#
USBlocksStraitofHormuz
745.55K Popularity
#
WCTCTradingChallengeShare8MUSDT
506.45K Popularity

Sitemap

5,900 Shares in Quest Diagnostics Incorporated $DGX Purchased by Capital Management Associates Inc

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin